<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88898</article-id><article-id pub-id-type="doi">10.7554/eLife.88898</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentration</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-291257"><name><surname>Rojekar</surname><given-names>Satish</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-291258"><name><surname>Pallapati</surname><given-names>Anusha R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-317837"><name><surname>Gimenez-Roig</surname><given-names>Judit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278226"><name><surname>Korkmaz</surname><given-names>Funda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291276"><name><surname>Sultana</surname><given-names>Farhath</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271157"><name><surname>Sant</surname><given-names>Damini</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-317838"><name><surname>Haeck</surname><given-names>Clement M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4856-1440</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271166"><name><surname>Macdonald</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230733"><name><surname>Kim</surname><given-names>Se-Min</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-228088"><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3436-8199</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-291385"><name><surname>Barak</surname><given-names>Orly</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271178"><name><surname>Meseck</surname><given-names>Marcia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271180"><name><surname>Caminis</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230739"><name><surname>Lizneva</surname><given-names>Daria</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-214885"><name><surname>Yuen</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-73636"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5911-9522</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><institution content-type="dept">Center for Translational Medicine and Pharmacology</institution>, <institution>Icahn School of Medicine at Mount Sinai</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Center for Biomedical Research</institution>, <institution>Population Council</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Center for Clinical and Translational Research</institution>, <institution>Maine Medical Center Research Institute</institution>, <addr-line><named-content content-type="city">Scarborough</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-160928"><name><surname>Huang</surname><given-names>Christopher L-H</given-names></name><role>Reviewing editor</role><aff><institution>University of Cambridge</institution>, <country>United Kingdom</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>satish.rojekar@mssm.edu</email> (SR);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>mone.zaidi@mountsinai.org</email> (MZ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>06</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e88898</elocation-id><history><date date-type="received"><day>25</day><month>04</month><year>2023</year></date><date date-type="accepted"><day>16</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Rojekar et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rojekar et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88898-v1.pdf"/><abstract><p>Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique formulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, and Alzheimer's disease. The studies were carried out using our Good Laboratory Practice (GLP) platform, compliant with the Code of Federal Regulations (Title 21, Part 58). We first used protein thermal shift, size exclusion chromatography, and dynamic light scattering to examine MS-Hu6 concentrations between 1 and 100 mg/mL. We found that thermal, monomeric, and colloidal stability of formulated MS-Hu6 was maintained at a concentration of 100 mg/mL. The addition of the antioxidant L-methionine and chelating agent disodium EDTA improved the formulation's long-term colloidal and thermal stability. Thermal stability was further confirmed by Nano differential scanning calorimetry (DSC). Physiochemical properties of formulated MS-Hu6, including viscosity, turbidity, and clarity, conformed with acceptable industry standards. That the structural integrity of MS-Hu6 in formulation was maintained was proven through Circular Dichroism (CD) and Fourier Transform Infrared (FTIR) spectroscopy. Three rapid freeze-thaw cycles at -80°C/25°C or -80°C/37°C further revealed excellent thermal and colloidal stability. Furthermore, formulated MS-Hu6, particularly its Fab domain, displayed thermal and monomeric storage stability for more than 90 days at 4°C and 25°C. Finally, the unfolding temperature (T<sub>m</sub>) for formulated MS-Hu6 increased by &gt;4.80°C upon binding to recombinant FSH, indicating highly specific ligand binding. Overall, we document the feasibility of developing a stable, manufacturable and transportable MS-Hu6 formulation at a ultra-high concentration at industry standards. The study should become a resource for developing biologic formulations in academic medical centers.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01 AG071870</award-id><principal-award-recipient><name><surname>Kim</surname><given-names>Se-Min</given-names></name><name><surname>Yuen</surname><given-names>Tony</given-names></name><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>R01 AG074092</award-id><principal-award-recipient><name><surname>Yuen</surname><given-names>Tony</given-names></name><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>U01AG073148</award-id><principal-award-recipient><name><surname>Yuen</surname><given-names>Tony</given-names></name><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000049</institution-id><institution>National Institute on Aging</institution></institution-wrap></funding-source><award-id>U19 AG060917</award-id><principal-award-recipient><name><surname>Rosen</surname><given-names>Clifford J</given-names></name><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01 DK113627</award-id><principal-award-recipient><name><surname>Zaidi</surname><given-names>Mone</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>P20 GM121301</award-id><principal-award-recipient><name><surname>Rosen</surname><given-names>Clifford J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Satish Rojekar, Is a co-inventor on a pending patent application relating to the ultra-high formulation of MS-Hu6.   These patents are owned by Icahn School of Medicine at Mount Sinai (ISMMS), and the inventors and co-inventors. would be recipients of royalties, per institutional policy..</p></fn><fn fn-type="conflict" id="conf3"><p>Se-Min Kim, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf4"><p>Daria Lizneva, Reviewing editor, <italic>eLife</italic>Is a co-inventor on a pending patent application relating to the effect LH on body composition..</p></fn><fn fn-type="conflict" id="conf5"><p>Tony Yuen, Senior editor, <italic>eLife</italic>Is a co-inventor on a pending patent application relating to the effect LH on body composition.  Is a co-inventor on a pending patent application relating to the ultra-high formulation of MS-Hu6.   These patents are owned by Icahn School of Medicine at Mount Sinai (ISMMS), and the inventors and co-inventors. would be recipients of royalties, per institutional policy..</p></fn><fn fn-type="conflict" id="conf6"><p>Mone Zaidi, Senior editor, <italic>eLife</italic>Is an inventor on issued patents on inhibiting FSH for the prevention and treatment of osteoporosis and obesity (U.S. Patents 8,435,948 and 11,034,761).  Is also an inventor on a patent application on the composition and use of humanized monoclonal anti-FSH antibodies and is a co-inventor of a pending patent on the use of FSH as a target for preventing Alzheimer's disease.  Is a co-inventor on a pending patent application relating to the effect LH on body composition.  Is a co-inventor on a pending patent application relating to the ultra-high formulation of MS-Hu6.   These patents are owned by Icahn School of Medicine at Mount Sinai (ISMMS), and the inventors and co-inventors. would be recipients of royalties, per institutional policy.  Also consults for Rani Pharmaceuticals, and several financial platforms, including Gerson Lehman Group and Guidepoint, on drugs for osteoporosis and genetic bone diseases..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 1-7.</p></sec><supplementary-material><ext-link xlink:href="elife-88898-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>